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The role of Xpert MTB/RIF in 
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Elisa López-Varela1,2, Inacio Mandomando1,7, Cesaltina Lorenzoni4, Jaume Ordi2,5, 
Clara Menéndez1,2, Quique Bassat1,2 & Miguel J. Martínez2,6
The extent to which the Xpert MTB/RIF (Gene Xpert) contributes to tuberculosis (TB) diagnosis in 
samples other than sputum and cerebrospinal fluid remains uncertain. We aimed to assess the role 
of Xpert MTB/RIF for detecting M. tuberculosis in post-mortem tissues. We conducted a study among 
30 complete diagnostic autopsies (CDA) performed at the Maputo Central Hospital (Mozambique). 
Lung tissues were screened for TB in all cases. In addition other tissues were tested when compatible 
lesions were identified in the histological exam. We used in-house real time PCR and LAMP assays to 
confirm the presence of M. tuberculosis DNA. The diagnosis of tuberculosis at death was established 
based on microbiological and histopathological results. Eight out of 30 cases (26.7%) were diagnosed 
of tuberculosis. Xpert had a sensitivity to detect TB in lung tissue of 87.5% (95% CI 47.3–99.7) and a 
specificity of 95.7% (95% CI: 78.1–99.9). In-house DNA amplification methods and Xpert showed 93.6% 
concordance for lung tissue and 100% concordance for brain and liver tissues. The final cause of death 
was attributable to tuberculosis in four cases. Xpert MTB/RIF may represent a valuable, easy-to perform 
technique for post-mortem TB diagnosis.
Tuberculosis (TB) remains a leading cause of morbidity and mortality, especially in low and middle-income 
countries. The World Health Organization (WHO) estimates that around one third of all TB cases remain undi-
agnosed or unreported1. Having highly sensitive and specific TB diagnostic tests would contribute to achieve the 
90% reduction in TB incidence by 2035, as established by the End-TB strategy2. Fortunately, after many years of 
limited progress on TB diagnostics, the last decade has witnessed renewed efforts on TB diagnostics development 
and assay evaluation3.
In 2010, the Xpert MTB/RIF assay (Cepheid, Sunnyvale, CA, USA. hereafter referred to as Xpert), a rapid, real 
time PCR-based diagnostic platform, was endorsed for the diagnosis of TB in sputum by the WHO4. A recent 
systematic review showed a pooled sensitivity of 89% and specificity of 99% for pulmonary TB diagnosis, against 
culture as gold standard5. The high sensitivity for TB diagnosis (especially for HIV infected TB cases) and the 
ability to detect mutations to rpoB gene (which confers resistance to Rifampicin, proxy of multi drug resistance) 
are key features that led to the roll out of this technology throughout the world. Several studies have analyzed the 
potential role of Xpert in blood6, cerebrospinal fluid7, urine8 or stool9, and other specimens10, which are potential 
alternatives for the diagnosis of TB, especially in the case of extra-pulmonary TB, HIV-TB co-infected patients 
or childhood TB. Although the latest WHO guidelines recommend that the Xpert assay should be used for test-
ing cerebrospinal fluid specimens from patients presumed to have TB meningitis11, the extent to which Xpert 
contributes to TB diagnosis in other samples remains uncertain. Likewise, the role of Xpert for TB diagnosis in 
postmortem tissues has been underexplored.
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Mozambique is one of the 22 TB high burden countries facing many challenges to achieve successful con-
trol1,12, showing high incidence rates, especially among HIV-infected patients13,14. The case detection rate has 
been estimated at 37%, thus very low certainty exists on mortality estimates1. In Mozambique as well as other high 
TB burden countries, a rapid, easy to perform and reliable technique that helps to establish TB diagnosis at death, 
could have a significant impact on the accuracy of global TB mortality statistics, and thus on health planning. 
Therefore, the objective of this study was to explore the utility of the Xpert assay for TB diagnosis in postmortem 
tissues in a high TB/HIV prevalence area.
Methods
This study is part of a large project aimed at validating minimally invasive autopsy (MIA) procedures for 
post-mortem investigation in Mozambique and Brazil15. The study included 30 adult patients who died at the 
Maputo Central Hospital (MCH) in November 2013. Briefly, assessment of the cause of death was performed to 
the two most recent deaths each morning (less than 24 hours from time of death) occurring in patients admitted 
for any cause at the MCH (excluding accidents or traumatic deaths), whose family had provided oral informed 
consent. A complete diagnostic autopsy (CDA) was performed to all cases. Further details on patient recruitment 
and methods of the larger study can be found elsewhere16.
Sample collection. Samples from lung, brain and liver were routinely collected from all cases during CDA. 
All samples from lung tissue were analyzed for molecular testing. In addition, any macroscopic lesion suggestive 
of tuberculosis in any of these organs was sampled and analysed with molecular tests. A first macroscopic evalua-
tion of the whole organ was conducted and then multiple sections of the organ were performed in order to sample 
lesions or areas with suspected lesions.
Sample Processing. For molecular microbiological analyses lung, brain and liver tissue samples were col-
lected in tubes containing lysis buffer (ATL buffer, Qiagen, Hildren, Germany). The volume of the tissue sam-
ples corresponded approximately to 0,5 ml. Tissue samples were thawed then homogenized using a handheld 
rotor-stator homogenizer (Tissue Ruptor, Qiagen), and disposable probes for each tissue sample processed. 
Nucleic acid extractions (DNA + RNA) were performed using a semi-automated system (Qiacube, Qiagen). In 
house real-time PCR was used following the procedures described by Espasa et al17. Loop-mediated isothermal 
amplification (LAMP) assay18 was used to confirm all positive conventional real time PCR results following the 
procedures described by Iwamoto and colleagues18. For the Xpert assay, sample preparation buffer was added to 
the homogenized samples in a 4:1 ratio, incubated at room temperature, and subsequently processed for Xpert 
testing as described by manufacturers19.
Tuberculosis case definitions. Tuberculosis disease at death was defined as presence of TB DNA through 
both in-house molecular methods (real time PCR and LAMP) in a given sample in addition to histologically 
compatible lesions (including inflammatory response). This case definition was considered the gold standard for 
the assessment of Xpert performance.
Tuberculosis as cause of death was defined when TB disease was present at death and the review of the entire 
post-mortem results and clinical data deemed this pathology as the most likely cause.
Data collection and analysis. We collected clinical information from all subjects using a standardized 
form, including age, sex, HIV status, previous TB history, current or past anti-tuberculosis treatment, TB compat-
ible symptoms, among others. HIV status was confirmed postmortem by an automated method (ADVIA Centaur 
HIV 1/0/2 Enhanced assay, Siemens Healthcare Diagnostics) and by PCR using the Cobas TaqMan HIV-1 test 
v2.0 (Roche Molecular Systems). The Xpert assay reports the detection of DNA from Mycobacterium tuberculosis 
complex (MTBC), the PCR cycle threshold (CT) as well as the presence of mutations of the rpoB gene. The results 
obtained after histopathological and microbiological examination were discussed by the study team composed 
by a pathologist, microbiologist, and epidemiologist and a physician specialized in tropical medicine. This team 
was blinded to the Xpert assay results, and based on the histological and microbiological results, determined the 
final cause of death for each case. The lab technologists who performed the Xpert tests were different from those 
participating in the overall study, and were not aware of the actual diagnosis of the cases. All clinical data and the 
results from the histopathological and microbiological examination of the samples were entered into a Microsoft 
Excel designed spreadsheet and then analyzed using Stata 13 (Stata Corp., College Station, TX). The diagnostic 
accuracy of the Xpert assay on lung tissue against the composite reference standard for pulmonary TB disease (the 
case definition) was calculated. The point sensitivity and specificity of Xpert was given with 95% exact binomial 
confidence intervals.
Ethical considerations. The protocol of the main study was approved by the National Mozambican Ethics 
Committee (ref. 342/CNBS/13) and the Ethics Committee of the Hospital Clinic of Barcelona, Spain. All study 
procedures and methods were carried out in accordance with the approved protocols and Ethics Committees’ 
existing guidelines.
Results
Out of the 30 cases, 12 (40%) were female and 19 (63.3%) were HIV-infected (higher HIV prevalence for males 
than for females: 77.8% vs 41.7% respectively, p = 0.04). The mean age at death was 40.3 years (range 17–76).
Eight of these 30 patients were diagnosed of TB (26.7%) according to the study case definition. Six (75.0%) of 
them were female and 6 (75.0%) were HIV positive. Clinical pre-mortem TB diagnosis was made in only one case, 
which was also the only case with documented anti-tuberculosis therapy. TB was the cause of death in 4 out of 
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the 8 cases (13.3% of whole series). Among the 19 HIV infected cases, 3 (15.8%) had TB as cause of death Table 1 
shows TB disease findings among the study cases.
Seven of the eight cases with TB at death tested positive with Xpert in lung tissue. There was an Xpert false 
negative case (case 10) in an HIV-infected patient whose cause of death was septic bacterial pneumonia due to 
Acinetobacter baumanni, but with both real time PCR and LAMP assays positive for TB. There was one case, 
which tested positive with Xpert and LAMP in lung tissue, but negative with in house PCR (all tests positive in 
brain tissue). No false positive results for Xpert were recorded. Thus, concordance between the results of Xpert 
and real time PCR occurred in 28 out of the 30 lung tissue cases (93.6%). The sensitivity of the Xpert assay to 
detect lungTB disease was 87.5% (95% CI 47.3–99.7) and the specificity was of 95.6% (95.7% CI: 78.1–99.9). Both 
in-house molecular methods and Xpert showed 100% concordance for liver (1 positive sample out of 1 tested) 
and brain tissues (3 positive for both methods out of 7 tested). None of the cases tested through Xpert showed 
mutation in the rpoB gene. Table 2 shows the results for Xpert and in-house molecular methods for all tubercu-
losis cases.
Discussion
To our knowledge this is the first study comparing the diagnostic accuracy of Xpert MTB/RIF with conventional 
real time PCR for TB diagnosis in tissue samples from autopsy cases of unknown cause of death. The study shows 
that 7 out of 8 TB cases were identified with Xpert, thus this assay may represent a valuable, easy-to perform tech-
nique for post-mortem TB diagnosis. Moreover, this study showed a high hidden burden of TB disease among 
cases with unknown cause of death, which draws attention as to the insufficient accuracy of the current methods 
used to estimate TB mortality worldwide.
The results of this study, which add to the limited knowledge of Xpert performance in non-liquid extrapulmo-
nary samples, show that Xpert may be a valuable assay in detecting MTB DNA from post-mortem lung, brain or 
Case # Age Sex HIV status Cause of death
TB Disease 
at death Positive Organs* Histology
Any clinical 
Diagnosis of TB
1 27 Male Infected Rhizopus oryzae cerebral mucormycosis Present Lung Pulmonary necrotizing granulomas No
2 76 Male Uninfected Cerebral infarction
3 30 Male Uninfected Hepatocellular carcinoma
4 19 Female Uninfected Cerebral toxoplasmosis
5 24 Female Uninfected Rheumatic valvular heart disease
6 28 Female Infected Disseminated Kaposi’s sarcoma (HHV-8) Yes
7 35 Female Infected Pneumocystis pneumonia
8 49 Male Uninfected Diabetic and hypertensive nephropathy
9 35 Female Infected Disseminated toxoplasmosis
10 27 Female Infected Pneumonia (Acinetobacter baumannii) Present Lung Pyogenic Pneumonia No
11 41 Male Uninfected Meningitis (Streptococcus pneumoniae) Yes
12 33 Male Infected CMV meningoencephalitis
13 76 Female Uninfected Cerebral hemorrhage
14 17 Female Infected Meningitis (Mycobacterium tuberculosis) Present Lung, Brain§ Pyogenic meningoencephalitis No
15 43 Male Infected Pneumocystis pneumonia
16 48 Male Uninfected Hepatocellular carcinoma
17 53 Female Infected Large B cell lymphoma Present Lung§ Pulmonary Necrotizing granulomas No
18 36 Female Infected Carcinoma (uterine cervix)
19 62 Male Uninfected Cerebral infarction
20 35 Male Infected Necrotizing adenoviral and cryptococcal pneumonia Yes
21 29 Female Infected Milliary tuberculosis Present Lung§, Brain, Liver Disseminated necrotizing granulomas No
22 61 Female Uninfected Tuberculous meningitis Present Lung, Brain Pyogenic meningoencephalitis
23 30 Female Infected Cryptococcal meningitis
24 74 Male Uninfected Gastric ulcer with upper gastrointestinal hemorrhage
25 57 Female Infected Carcinoma (uterine cervix)
26 45 Female Infected Milliary tuberculosis Present Lung§, Brain, Liver Disseminated necrotizing granulomas No
27 27 Female Infected Puerperal sepsis
28 29 Female Infected Cryptococcal sepsis
29 32 Male Infected S.disgalactiae sepsis Present Lung Pumonary necrotizing granulomas Yes
30 30 Female Infected Cerebral toxoplasmosis
Table 1. Characteristics and cause of death of patients included in the study. *By in-house RT PCR or 
LAMP. §Positive Ziehl-Neelsen stain on histological slides.
www.nature.com/scientificreports/
4Scientific RepoRts | 6:20703 | DOI: 10.1038/srep20703
liver tissue. These findings also support those of a recent autopsy study showing that all TB cases diagnosed through 
histopathological examination were also Xpert positive in postmortem tissues, although that study did not use a 
conventional method to confirm TB20. However, another study by Yagmur and colleagues comparing real time PCR 
vs Xpert in paraffin-embedded tissues showed limited sensitivity of both tests (against TB defined by histopathologic 
findings), which could be attributable to the method of preserving the samples21. Although of small sample size, 
some reports have shown the good performance of Xpert in non-liquid specimens, such as lymphadenopathies22, 
joint and bone23, or other tissues24,25. According to the CT values, Xpert detected M. tuberculosis in most of the sam-
ples with high, low and medium detection levels, potentially reflecting a high bacillary load in the tissues analysed26. 
One case with high CT value in lung tissue, which arguable could have been considered a false positive, had a low CT 
in brain tissue and also showed acid fast bacilli and TB histopathological compatible lesions.
In this study there were four cases of TB disease without any of the clinical diagnoses being TB and with a 
cause of death other than TB. The latter could be explained by the unspecific presentation of TB, often atypical in 
HIV-infected patients (all of them were HIV-infected), or perhaps masked by symptoms caused by the actual cause 
of death. In one of these cases the real time PCR and LAMP were positive in lung tissue without any typical TB 
compatible lesions, but with inflammatory response at histological examination. Histologically compatible lesions 
might not have been found due to the strong immunosuppression associated to advanced AIDS, although not all 
lung tissue was examined under the microscope due to the absence of macroscopically compatible lesions. Although 
some might argue that this could be a case of latent TB infection27, we believe we cannot diagnose it with currently 
available diagnostic tools28. With a bacterial load high enough to be detected by real time PCR and LAMP, we 
suggest this could represent a case of emerging TB disease, one of the middle states of the continuum whose ends 
are latent TB infection and active TB disease29. Regardless of whether any of these four cases could have been diag-
nosed of TB before death, these results show a considerable hidden burden of TB disease at death. Moreover, only 
one of the 4 cases having died of TB had been diagnosed with TB pre-mortem. This goes in line with findings from 
a recent autopsy study in Zambian adults showing that 26% of cases with TB had not been clinically diagnosed20. 
Importantly, three non-TB cases were misdiagnosed as tuberculosis by clinicians (2 as main diagnosis and 1 as main 
secondary diagnosis), but no evidence of TB was found in the post-mortem analysis.
This study had several limitations. First, the sample size is limited and hinders any robust conclusions, espe-
cially for tissues other than lungs. Second, liquid culture was not used in this study, which would have been a bet-
ter gold standard against to compare both Xpert and in-house molecular methods. Likewise, the use of genome 
sequencing would also have allowed to better characterize the MTB strains involved, as well as provide further 
robustness to the gold standard. However this was not possible due to the agreed conditions for shipment and 
analysis of samples of the larger autopsy study. Third, the fact that Xpert is a real time PCR, and the principals of 
molecular detection are somewhat similar to the conventional PCR, could have led to certain incorporation bias. 
We believe that the composite nature of our gold standard could have contribute to minimize the potential bias 
of our Xpert performance estimates. Lastly, it was difficult to infer whether the sample processing strategy was 
suboptimal (ie. ratio of inactivation buffer/sample, sample volume) or to what extend the conditions of sample 
storage (in lysis buffer solution) could affect the performance of both the tests. Taking into account the histo-
pathological examination and the excellent concordance of both tests, it is unlikely that the latter limitation would 
significantly affect the study results.
In conclusion, Xpert seems to be a reliable method for TB post-mortem diagnosis, more rapid and easy to 
perform than conventional molecular methods. This study also shows that in high TB and HIV endemic coun-
tries, TB disease may be significantly underdiagnosed and often misdiagnosed. For individual and public health 
benefits, there is a need to develop and more widely apply new methods to reliably estimate TB mortality.
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